메뉴 건너뛰기




Volumn , Issue , 2013, Pages 333-346

Screening for prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84929044865     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-2864-9_27     Document Type: Chapter
Times cited : (2)

References (58)
  • 3
    • 49549125242 scopus 로고
    • Principles and practice of screening for disease
    • Wilson JM, Jungner YG. Principles and practice of screening for disease. WHO Chron. 1968;22(11):473.
    • (1968) WHO Chron. , vol.22 , Issue.11 , pp. 473
    • Wilson, J.M.1    Jungner, Y.G.2
  • 4
    • 70350450970 scopus 로고    scopus 로고
    • Prostate specific antigen best practice statement: 2009 update
    • Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182(5): 2232-41.
    • (2009) J Urol. , vol.182 , Issue.5 , pp. 2232-2241
    • Greene, K.L.1    Albertsen, P.C.2    Babaian, R.J.3
  • 5
    • 77949363162 scopus 로고    scopus 로고
    • American Cancer Society guideline for the early detection of prostate cancer: Update 2010
    • Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98.
    • (2010) CA Cancer J Clin. , vol.60 , Issue.2 , pp. 70-98
    • Wolf, A.M.1    Wender, R.C.2    Etzioni, R.B.3
  • 6
    • 67649446263 scopus 로고    scopus 로고
    • European Association of Urology position statement on screening for prostate cancer
    • Abrahamsson PA, Artibani W, Chapple CR, Wirth M. European Association of Urology position statement on screening for prostate cancer. Eur Urol. 2009;56(2):270-1.
    • (2009) Eur Urol. , vol.56 , Issue.2 , pp. 270-271
    • Abrahamsson, P.A.1    Artibani, W.2    Chapple, C.R.3    Wirth, M.4
  • 7
    • 33645128572 scopus 로고    scopus 로고
    • Brief report: Physicians and their personal prostate cancer-screening practices with prostatespecific antigen
    • Chan EC, Barry MJ, Vernon SW, Ahn C. Brief report: physicians and their personal prostate cancer-screening practices with prostatespecific antigen. A national survey. J Gen Intern Med. 2006;21(3): 257-9.
    • (2006) A National Survey. J Gen Intern Med. , vol.21 , Issue.3 , pp. 257-259
    • Chan, E.C.1    Barry, M.J.2    Vernon, S.W.3    Ahn, C.4
  • 8
    • 41549136821 scopus 로고    scopus 로고
    • Use of the prostate-specific antigen test among U. S. men:findings from the 2005 National Health Interview Survey
    • Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men:findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(3):636-44.
    • (2008) Cancer Epidemiol Biomarkers Prev. , vol.17 , Issue.3 , pp. 636-644
    • Ross, L.E.1    Berkowitz, Z.2    Ekwueme, D.U.3
  • 9
    • 2642551798 scopus 로고    scopus 로고
    • Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: A cross-sectional study
    • Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 2004;94(1):51-6.
    • (2004) BJU Int. , vol.94 , Issue.1 , pp. 51-56
    • Melia, J.1    Moss, S.2    Johns, L.3
  • 10
    • 0025849053 scopus 로고
    • Measurement of prostatespecific antigen in serum as a screening test for prostate cancer
    • Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostatespecific antigen in serum as a screening test for prostate cancer. N Eng J Med. 1991;324(17):1156-61.
    • (1991) N Eng J Med. , vol.324 , Issue.17 , pp. 1156-1161
    • Catalona, W.J.1    Smith, D.S.2    Ratliff, T.L.3
  • 11
    • 2442715038 scopus 로고    scopus 로고
    • Prevalence of prostate cancer among men with a prostate-specific antigen level £ 4. 0 ng per milliliter
    • Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level £ 4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-46.
    • (2004) N Engl J Med. , vol.350 , Issue.22 , pp. 2239-2246
    • Thompson, I.M.1    Pauler, D.K.2    Goodman, P.J.3
  • 12
    • 0037016030 scopus 로고    scopus 로고
    • Screening for prostate cancer: An update of the evidence for the U. S. Preventive Services Task Force
    • Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(11):917-29.
    • (2002) Ann Intern Med. , vol.137 , Issue.11 , pp. 917-929
    • Harris, R.1    Lohr, K.N.2
  • 13
    • 34249286193 scopus 로고    scopus 로고
    • Epidemiology of prostate cancer in Africa: Another step in the understanding of the disease?
    • Delongchamps NB, Singh A, Haas GP. Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer. 2007;31(3):226-36.
    • (2007) Curr Probl Cancer. , vol.31 , Issue.3 , pp. 226-236
    • Delongchamps, N.B.1    Singh, A.2    Haas, G.P.3
  • 14
    • 35148846265 scopus 로고    scopus 로고
    • Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence
    • Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007;99(19):1484-9.
    • (2007) J Natl Cancer Inst. , vol.99 , Issue.19 , pp. 1484-1489
    • Haas, G.P.1    Delongchamps, N.B.2    Jones, R.F.3
  • 15
    • 49049090790 scopus 로고    scopus 로고
    • U.S. Preventative services task force. Screening for prostate cancer: U.S. Preventative Services Task Force recommendation statement
    • U.S. Preventative Services Task Force. Screening for prostate cancer: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med. 2008;149:185-91.
    • (2008) Ann Intern Med. , vol.149 , pp. 185-191
  • 16
    • 63249118690 scopus 로고    scopus 로고
    • Screening and prostate-cancer mortality in a randomized European study
    • Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8.
    • (2009) N Engl J Med. , vol.360 , Issue.13 , pp. 1320-1328
    • Schröder, F.H.1    Hugosson, J.2    Roobol, M.J.3
  • 19
    • 37349005496 scopus 로고    scopus 로고
    • Characteristics of prostate cancer detected by digital rectal examination only
    • Okotie OT, Roehl KA, Han M, et al. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007;70(6):1117-20.
    • (2007) Urology. , vol.70 , Issue.6 , pp. 1117-1120
    • Okotie, O.T.1    Roehl, K.A.2    Han, M.3
  • 20
    • 70349667018 scopus 로고    scopus 로고
    • A systematic review of the diagnostic accuracy of prostate specific antigen
    • Harvey P, Basuita A, Endersby D, et al. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol. 2009;9:14-23.
    • (2009) BMC Urol. , vol.9 , pp. 14-23
    • Harvey, P.1    Basuita, A.2    Endersby, D.3
  • 21
    • 0027244140 scopus 로고
    • Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges
    • Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860-4.
    • (1993) JAMA. , vol.270 , Issue.7 , pp. 860-864
    • Oesterling, J.E.1    Jacobsen, S.J.2    Chute, C.G.3
  • 22
    • 0028801975 scopus 로고
    • A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
    • Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273(4):289-94.
    • (1995) JAMA. , vol.273 , Issue.4 , pp. 289-294
    • Gann, P.H.1    Hennekens, C.H.2    Stampfer, M.J.3
  • 23
    • 23244433208 scopus 로고    scopus 로고
    • Prostate-specific antigen levels in the United States: Implications of various definitions for abnormal
    • Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005;97(15):1132-7.
    • (2005) J Natl Cancer Inst. , vol.97 , Issue.15 , pp. 1132-1137
    • Welch, H.G.1    Schwartz, L.M.2    Woloshin, S.3
  • 24
    • 70349637766 scopus 로고    scopus 로고
    • Prostate specific antigen for early detection of prostate cancer: Longitudinal study
    • Holmstrom B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ. 2009;339:b3537.
    • (2009) BMJ. , vol.339 , pp. b3537
    • Holmstrom, B.1    Johansson, M.2    Bergh, A.3    Stenman, U.H.4    Hallmans, G.5    Stattin, P.6
  • 25
    • 31944436853 scopus 로고    scopus 로고
    • Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old
    • Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67(2):316-20.
    • (2006) Urology. , vol.67 , Issue.2 , pp. 316-320
    • Loeb, S.1    Roehl, K.A.2    Antenor, J.A.3    Catalona, W.J.4    Suarez, B.K.5    Nadler, R.B.6
  • 26
    • 77956811462 scopus 로고    scopus 로고
    • Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
    • Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010;341:c4521.
    • (2010) BMJ. , vol.341 , pp. c4521
    • Vickers, A.J.1    Cronin, A.M.2    Bjork, T.3
  • 27
    • 0141763756 scopus 로고    scopus 로고
    • Interval carcinomas in the European randomized study of screening for prostate cancer (ERSPC)-Rotterdam
    • van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH. Interval carcinomas in the European randomized study of screening for prostate cancer (ERSPC)-Rotterdam. J Natl Cancer Inst. 2003;95(19):1462-6.
    • (2003) J Natl Cancer Inst. , vol.95 , Issue.19 , pp. 1462-1466
    • Van Der Cruijsen-Koeter, I.W.1    Van Der Kwast, T.H.2    Schroder, F.H.3
  • 28
    • 34548581216 scopus 로고    scopus 로고
    • Interval cancers in prostate cancer screening: Comparing 2-and 4-year screening intervals in the European randomized study of screening for prostate cancer, Gothenburg and Rotterdam
    • Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2-and 4-year screening intervals in the European randomized study of screening for prostate cancer, Gothenburg and Rotterdam. J Natl Cancer Inst. 2007;99(17):1296-303.
    • (2007) J Natl Cancer Inst. , vol.99 , Issue.17 , pp. 1296-1303
    • Roobol, M.J.1    Grenabo, A.2    Schroder, F.H.3    Hugosson, J.4
  • 29
    • 63249122661 scopus 로고    scopus 로고
    • Mortality results from a randomized prostate-cancer screening trial
    • Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9.
    • (2009) N Engl J Med. , vol.360 , Issue.13 , pp. 1310-1319
    • Andriole, G.L.1    Crawford, E.D.2    Grubb, R.L.3
  • 31
    • 69249209651 scopus 로고    scopus 로고
    • Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European randomised study of screening for prostate cancer (ERSPC)
    • Roobol MJ, Kerkhof M, Schröder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European randomised study of screening for prostate cancer (ERSPC). Eur Urol. 2009;56(4):584-91.
    • (2009) Eur Urol. , vol.56 , Issue.4 , pp. 584-591
    • Roobol, M.J.1    Kerkhof, M.2    Schröder, F.H.3
  • 32
    • 33846271431 scopus 로고    scopus 로고
    • Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial
    • Aus G, Bergdahl S, Lodding P, et al. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol. 2007;51:659-64.
    • (2007) Eur Urol. , vol.51 , pp. 659-664
    • Aus, G.1    Bergdahl, S.2    Lodding, P.3
  • 33
    • 77955279420 scopus 로고    scopus 로고
    • Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
    • Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-32.
    • (2010) Lancet Oncol. , vol.11 , Issue.8 , pp. 725-732
    • Hugosson, J.1    Carlsson, S.2    Aus, G.3
  • 34
    • 77952862416 scopus 로고    scopus 로고
    • ERSPC and PLCO prostate cancer screening studies: What are the differences?
    • Schroder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol. 2010;58(1):46-52.
    • (2010) Eur Urol. , vol.58 , Issue.1 , pp. 46-52
    • Schroder, F.H.1    Roobol, M.J.2
  • 35
    • 0037027158 scopus 로고    scopus 로고
    • Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in twofixed cohorts from Seattle area and Connecticut
    • Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in twofixed cohorts from Seattle area and Connecticut. BMJ. 2002; 325(7367):740.
    • (2002) BMJ. , vol.325 , Issue.7367 , pp. 740
    • Lu-Yao, G.1    Albertsen, P.C.2    Stanford, J.L.3    Stukel, T.A.4    Walker-Corkery, E.S.5    Barry, M.J.6
  • 36
    • 56749163379 scopus 로고    scopus 로고
    • Screening, treatment and prostate cancer mortality in the Seattle area and Connecticut:fifteen year follow-up
    • Lu-Yao G, Albertsen PC, Stanford JL, et al. Screening, treatment and prostate cancer mortality in the Seattle area and Connecticut:fifteen year follow-up. J Gen Intern Med. 2008;23(11):1809-14.
    • (2008) J Gen Intern Med. , vol.23 , Issue.11 , pp. 1809-1814
    • Lu-Yao, G.1    Albertsen, P.C.2    Stanford, J.L.3
  • 37
    • 8444233301 scopus 로고    scopus 로고
    • Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden
    • discussion 724
    • Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46(6):717-23; discussion 724.
    • (2004) Eur Urol. , vol.46 , Issue.6 , pp. 717-723
    • Sandblom, G.1    Varenhorst, E.2    Lofman, O.3    Rosell, J.4    Carlsson, P.5
  • 38
    • 0022460772 scopus 로고
    • Fine needle aspiration biopsy of the prostate gland: A study of 103 cases with histological follow up
    • Ljung BM, Cherrie R, Kaufman JJ. Fine needle aspiration biopsy of the prostate gland: a study of 103 cases with histological follow up. J Urol. 1986;135(5):955-8.
    • (1986) J Urol. , vol.135 , Issue.5 , pp. 955-958
    • Ljung, B.M.1    Cherrie, R.2    Kaufman, J.J.3
  • 39
    • 1942539318 scopus 로고    scopus 로고
    • Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial
    • Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59(3):311-8.
    • (2004) Prostate. , vol.59 , Issue.3 , pp. 311-318
    • Labrie, F.1    Candas, B.2    Cusan, L.3
  • 40
    • 33748082979 scopus 로고    scopus 로고
    • Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostatespecific antigen testing
    • Oberaigner W, Horninger W, Klocker H, et al. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostatespecific antigen testing. Am J Epidemiol. 2006;164(4):376-84.
    • (2006) Am J Epidemiol. , vol.164 , Issue.4 , pp. 376-384
    • Oberaigner, W.1    Horninger, W.2    Klocker, H.3
  • 41
    • 0002855014 scopus 로고
    • 1931-1971: A critical review, with particular reference to the medical profession
    • London: Office of Health Economics
    • Cochrane AL. 1931-1971: a critical review, with particular reference to the medical profession. In: Medicines for the year 2000. London: Office of Health Economics; 1979. p. 1-11.
    • (1979) Medicines for the Year 2000 , pp. 1-11
    • Cochrane, A.L.1
  • 43
    • 77956810216 scopus 로고    scopus 로고
    • Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials
    • Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.
    • (2010) BMJ. , vol.341 , pp. c4543
    • Djulbegovic, M.1    Beyth, R.J.2    Neuberger, M.M.3
  • 44
    • 0037014792 scopus 로고    scopus 로고
    • Overdiagnosis due to prostate-specific antigen screening: Lessons from U. S. Prostate cancer incidence trends
    • Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. Prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-90.
    • (2002) J Natl Cancer Inst. , vol.94 , Issue.13 , pp. 981-990
    • Etzioni, R.1    Penson, D.F.2    Legler, J.M.3
  • 45
    • 70349941075 scopus 로고    scopus 로고
    • Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005
    • Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325-9.
    • (2009) J Natl Cancer Inst. , vol.101 , Issue.19 , pp. 1325-1329
    • Welch, H.G.1    Albertsen, P.C.2
  • 46
    • 64949135826 scopus 로고    scopus 로고
    • Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context
    • Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-83.
    • (2009) J Natl Cancer Inst. , vol.101 , Issue.6 , pp. 374-383
    • Draisma, G.1    Etzioni, R.2    Tsodikov, A.3
  • 47
    • 0038275923 scopus 로고    scopus 로고
    • Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European randomized study of screening for prostate cancer
    • Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst. 2003;95(12):868-78.
    • (2003) J Natl Cancer Inst. , vol.95 , Issue.12 , pp. 868-878
    • Draisma, G.1    Boer, R.2    Otto, S.J.3
  • 48
    • 4644287961 scopus 로고    scopus 로고
    • Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study
    • Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358-67.
    • (2004) J Natl Cancer Inst. , vol.96 , Issue.18 , pp. 1358-1367
    • Potosky, A.L.1    Davis, W.W.2    Hoffman, R.M.3
  • 49
    • 70449525320 scopus 로고    scopus 로고
    • A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer
    • Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79-85.
    • (2010) Eur Urol. , vol.57 , Issue.1 , pp. 79-85
    • Roobol, M.J.1    Steyerberg, E.W.2    Kranse, R.3
  • 50
    • 33845312324 scopus 로고    scopus 로고
    • External validation of the prostate cancer prevention trial risk calculator in a screened population
    • Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the prostate cancer prevention trial risk calculator in a screened population. Urology. 2006;68(6):1152-5.
    • (2006) Urology. , vol.68 , Issue.6 , pp. 1152-1155
    • Parekh, D.J.1    Ankerst, D.P.2    Higgins, B.A.3
  • 51
    • 34547736129 scopus 로고    scopus 로고
    • Risk factors for prostate cancer incidence and progression in the health professionals follow-up study
    • Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7): 1571-8.
    • (2007) Int J Cancer. , vol.121 , Issue.7 , pp. 1571-1578
    • Giovannucci, E.1    Liu, Y.2    Platz, E.A.3    Stampfer, M.J.4    Willett, W.C.5
  • 52
    • 18544377048 scopus 로고    scopus 로고
    • Germline mutations in the ribonuclease L gene in families showing linkage with HPC1
    • Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002;30(2):181-4.
    • (2002) Nat Genet. , vol.30 , Issue.2 , pp. 181-184
    • Carpten, J.1    Nupponen, N.2    Isaacs, S.3
  • 53
    • 0037222306 scopus 로고    scopus 로고
    • Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
    • Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72(1):1-12.
    • (2003) Am J Hum Genet. , vol.72 , Issue.1 , pp. 1-12
    • Edwards, S.M.1    Kote-Jarai, Z.2    Meitz, J.3
  • 54
    • 78650657873 scopus 로고    scopus 로고
    • Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study
    • Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int. 2011;107(1):28-39.
    • (2011) BJU Int. , vol.107 , Issue.1 , pp. 28-39
    • Mitra, A.V.1    Bancroft, E.K.2    Barbachano, Y.3
  • 55
    • 58549118238 scopus 로고    scopus 로고
    • Prostate cancer genomics: Towards a new understanding
    • Witte JS. Prostate cancer genomics: towards a new understanding. Nat Rev Genet. 2009;10(2):77-82.
    • (2009) Nat Rev Genet. , vol.10 , Issue.2 , pp. 77-82
    • Witte, J.S.1
  • 56
    • 39749129053 scopus 로고    scopus 로고
    • Multiple newly identified loci associated with prostate cancer susceptibility
    • Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316-21.
    • (2008) Nat Genet. , vol.40 , Issue.3 , pp. 316-321
    • Eeles, R.A.1    Kote-Jarai, Z.2    Giles, G.G.3
  • 57
    • 78149451143 scopus 로고    scopus 로고
    • The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine
    • Whitaker HC, Kote-Jarai Z, Ross-Adams H, et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One. 2010;5(10):e13363. doi: 10.1371/journal.pone.0013363 .
    • (2010) PLoS One. , vol.5 , Issue.10 , pp. e13363
    • Whitaker, H.C.1    Kote-Jarai, Z.2    Ross-Adams, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.